BRIEF published on 04/07/2026 at 07:05, 6 months 7 days ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 6 months 7 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months 7 days ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months 7 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 6 months 24 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 6 months 24 days ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 6 months 24 days ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 6 months 24 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 9 months 2 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 9 months 2 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 10/14/2026 at 15:40, 6 hours 3 minutes ago Galway Metals Announces Closing of $14 Million Brokered Private Placement Led by Michael Gentile
Published on 10/14/2026 at 15:00, 6 hours 43 minutes ago Route1 Provides Operating and Market Update; Outlines Q4 2026 Priorities
Published on 10/14/2026 at 15:00, 6 hours 43 minutes ago Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Published on 10/14/2026 at 14:50, 6 hours 53 minutes ago AIAI Holdings to Present at the 20th Annual LD Micro Main Event
Published on 10/14/2026 at 14:30, 7 hours 13 minutes ago Boron One Holdings Inc. Announces Positive Preliminary Economic Assessment (PEA) for Its Piskanja Boron Project
Published on 10/14/2026 at 19:32, 2 hours 11 minutes ago EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2026: Earnings below prior year – net sales up – forecast confirmed
Published on 10/14/2026 at 19:05, 2 hours 37 minutes ago Bulgin Introduces 6000 Series Hybrid Buccaneer Connectors for Power and Signal Connectivity
Published on 10/14/2026 at 19:00, 2 hours 43 minutes ago Informations relatives à l’augmentation de capital
Published on 10/14/2026 at 18:43, 2 hours 59 minutes ago Jean-Marc Bellaiche to become new CEO of the DOUGLAS Group - Sander van der Laan to retire
Published on 10/14/2026 at 18:00, 3 hours 43 minutes ago CIS : Chiffre d’affaires du 3ème trimestre 2026 supérieur aux attentes : accélération de la croissance et visibilité renforcée.
Published on 10/14/2026 at 18:00, 3 hours 43 minutes ago CIS : Q3 2026 revenue higher than expected: accelerated growth and increased visibility.
Published on 10/14/2026 at 17:40, 4 hours 3 minutes ago Mersen obtient la certification internationale Living Wage pour son engagement en faveur du bien-être de ses collaborateurs
Published on 10/14/2026 at 17:40, 4 hours 3 minutes ago Mersen’s commitment to employee well-being earns it international Living Wage certification
